Paecilomyces hepiali
Paecilomyces hepiali
Paecilomyces hepiali is a fungal species that has been studied for its potential medicinal properties. While traditional uses of this plant are not well-documented, research suggests it may have applications in liver health and immunity. In vitro and in vivo studies indicate that Paecilomyces hepiali Chen (Cs-4) polysaccharides can reduce liver fibrosis markers by inhibiting HSCs activation via TGF-β1/Smad and NLRP3/Caspase-1 pathways, although the strength of this evidence is still being evaluated. Additionally, certain strains of Paecilomyces hepiali, such as PH4477, can degrade phenylacetate into 2-hydroxyphenylacetate and 4-hydroxyphenylacetate, which may have metabolic benefits. Probiotic supplementation with Paecilomyces hepiali has shown potential in improving gut microbiota composition and enhancing immunity in immunosuppressed mice, but further research is needed to confirm these findings. No major safety issues or known drug interactions have been recorded for this fungus.
- Best evidence
- A
- Cautions
- —
Informational only. Traditional use does not mean proven effectiveness. Evidence and safety vary — check the cited sources.
What the science says
- Paecilomyces hepiali PH4477 and other fungal strains efficiently degrade phenylacetate, producing 2-hydroxyphenylacetate and 4-hydroxyphenylacetate as major metabolic products.
- Probiotic supplementation showed potential benefits in improving serum creatinine, insulin resistance, lipid profiles, and reducing inflammatory markers in diabetic kidney disease patients, but larger studies are needed.
- Paecilomyces hepiali Chen (Cs-4) polysaccharides reduced liver fibrosis by inhibiting TGF-β1/Smad and NLRP3/Caspase-1 pathways in both in vivo and in vitro models.
- The study found that Paecilomyces hepiali showed higher total antioxidant capacity compared to other samples.
- PHP from P. hepiali showed potential in regulating immunity and gut microbiota in cyclophosphamide-induced mice by modulating cytokine secretion and tight junction protein expression.
Frequently asked questions
What is Paecilomyces hepiali?
Paecilomyces hepiali (Paecilomyces hepiali) is a plant documented in FolkKB's traditional-medicine reference, drawn from sourced literature and cross-checked against the evidence.
What does the scientific evidence say about Paecilomyces hepiali?
5 sourced findings are recorded for Paecilomyces hepiali; the strongest carries evidence grade A. For example: Paecilomyces hepiali PH4477 and other fungal strains efficiently degrade phenylacetate, producing 2-hydroxyphenylacetate and 4-hydroxyphenylacetate as major metabolic products.
How strong is the evidence for Paecilomyces hepiali?
The strongest finding for Paecilomyces hepiali carries evidence grade A — strong evidence. Grades run A (strongest) to D (preliminary or traditional).
Is Paecilomyces hepiali safe? What are the side effects?
No major safety issues are recorded for Paecilomyces hepiali in our sources, but the data may be incomplete. Consult a qualified professional before use.
Does Paecilomyces hepiali interact with medications?
No drug interactions are recorded for Paecilomyces hepiali in our sources. This does not rule them out — check with a pharmacist.
Is Paecilomyces hepiali a proven treatment?
No. FolkKB is informational only. Traditional use and early findings are not proof of efficacy or safety — consult a qualified professional and never self-treat.
Sources
- T2 Positive effects of extracellular polysaccharides from Paecilomyces hepiali on immune-enhancing properties by regulating gut microbiota in cyclophosphamide-induced mice. literature abstract metadata
- T2 Analysis of Metabolic Profiles and Antioxidant Activity of Chinese Cordyceps, Ophiocordyceps sinensis, and Paecilomyces hepiali Based on Untargeted Metabolomics. literature abstract metadata
- T2 Fungal degradation of phenylacetate focusing on CRISPR/Cas9-assisted characterization of two oxidative enzyme genes of Akanthomyces muscarius AM1091. literature abstract metadata
- T2 Paecilomyces hepiali Chen (Cs-4) polysaccharides ameliorate chronic liver fibrosis via inhibiting TGF-β1/Smad and NLRP3/Caspase-1-mediated hepatic stellate cells activation in vivo and in vitro. literature abstract metadata
- T2 Effects of probiotic supplementation on diabetic kidney disease: a systematic review and meta-analysis of randomized controlled trials. literature abstract metadata